1 |
Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013;62:479-491.
DOI
|
2 |
Berthold HK, Gouni-Berthold I. Hyperlipoproteinemia(a): clinical significance and treatment options. Atheroscler Suppl 2013;14:1-5.
DOI
|
3 |
Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016 Sep 27 [Epub]. http://doi.org/10.1194/jlr.R071233.
DOI
|
4 |
Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607-614.
|
5 |
Guan W, Cao J, Steffen BT, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:996-1001.
DOI
|
6 |
Lim TS, Yun JS, Cha SA, et al. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med 2016;31:1110-1119.
DOI
|
7 |
Lee HJ, Pae JC, Sung KC, et al. Distribution of serum lipoprotein(a) level and its association with other risk factors in apparently healthy Korean. Korean Circ J 2006;36:150-158.
DOI
|
8 |
Haffner SM, Morales PA, Stern MP, Gruber MK. Lp(a) concentrations in NIDDM. Diabetes 1992;41:1267-1272.
DOI
|
9 |
Ding L, Song A, Dai M, et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res 2015;56:920-926.
DOI
|
10 |
Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993;87:1135-1141.
DOI
|
11 |
Marcovina SM, Albers JJ, Jacobs DR Jr, et al. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans: the CARDIA study. Arterioscler Thromb 1993;13:1037-1045.
DOI
|
12 |
Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
DOI
|
13 |
Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1139-1158.
DOI
|
14 |
AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
DOI
|
15 |
Ko HS, Kim CJ, Ryu WS. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function. J Cardiovasc Pharmacol 2005;46:405-411.
DOI
|